Physician profile
Robert E Fintelmann
NPI 1497971535
$3,889.40
in general payments reported to CMS, 2019-2025
10 companies · $52.03 in 2025
The $52.03 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42.07 · 2020: $40.40 · 2021: $29.35 · 2023: $922 · 2024: $2,803 · 2025: $52.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Charitable Contribution: $2,778 · Consulting Fee: $900 · Food and Beverage: $38.42 · Gift: $36.06 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Charitable Contribution | $2,777.51 |
| Consulting Fee | $900.00 |
| Food and Beverage | $38.42 |
| Gift | $36.06 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Microsurgical Technology, INC. | $2,777.51 | 2024 | |
| Beaver-Visitec International, INC. | $900.00 | 2023 | |
| Carl Zeiss Meditec USA, INC. | $65.41 | 2021-2025 | Visumax |
| Rxsight INC | $25.59 | 2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Light Adjustable Lens (Lal) |
| Dompe US, INC. | $25.11 | 2019 | |
| Alcon Vision LLC | $24.11 | 2020 | |
| Biotissue Holdings INC. | $22.45 | 2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $16.96 | 2019 | |
| Ivantis, INC | $16.29 | 2020 | |
| Glaukos Corporation | $15.97 | 2025 | Photrexa Viscous and Photrexa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Fintelmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.